Olumiant (Baricitinib) is a prescription medication belonging to the Janus kinase (JAK) inhibitor class. It works by modifying specific immune system signalling pathways involved in inflammation and immune responses. Baricitinib is used for certain inflammatory and autoimmune conditions, including moderately to severely active rheumatoid arthritis and severe alopecia areata, depending on local regulatory approval.
Olumiant is manufactured by Eli Lilly and Company and is available in different tablet strengths. It should only be used under the supervision of a qualified healthcare professional.
| Brand Name | Olumiant |
| Generic Name | Baricitinib |
| Drug Class | Janus Kinase (JAK) Inhibitor |
| Active Ingredient | Baricitinib |
| Dosage Form | Oral Tablets |
| Available Strengths | 2 mg and 4 mg (market availability may vary) |
| Route of Administration | Oral |
| Manufacturer | Eli Lilly and Company |
| Prescription Requirement | Prescription Only |
| Therapeutic Category | Immunomodulator |
Olumiant is used to treat certain medical conditions involving abnormal immune system activity. Its approved uses vary by country.
Olumiant contains baricitinib, which selectively inhibits Janus kinase enzymes, particularly JAK1 and JAK2. These enzymes participate in cellular signalling pathways that regulate immune responses and inflammation.
By inhibiting these pathways, baricitinib reduces the activity of certain inflammatory signals in the body. This action can help reduce autoimmune inflammation and improve symptoms associated with approved conditions.
Treatment response varies between individuals. Results depend on the underlying condition, treatment duration and individual medical factors.
The appropriate dosage depends on the condition being treated, age, kidney function, laboratory results and individual treatment response. The following are US prescribing-label recommendations and are not instructions for self-medication.
| Medical Condition | US Label Dosage |
|---|---|
| Rheumatoid Arthritis | 2 mg once daily |
| Severe Alopecia Areata | 2 mg once daily, with possible adjustment to 4 mg under medical supervision |
| Hospitalized COVID-19 Patients | 4 mg once daily for up to 14 days or until hospital discharge, whichever occurs first |
Important: These doses are indication-specific US label recommendations. Local approvals and prescribing recommendations may differ. Never start, increase, decrease or discontinue Olumiant without consulting your doctor.
Like other prescription medicines, Olumiant may cause side effects. Some are mild, while others may require immediate medical attention.
Commonly Reported Side Effects:Seek immediate medical attention if you experience difficulty breathing, chest pain, sudden weakness, swelling or pain in one leg, severe infection symptoms or other serious unexpected symptoms.
Olumiant affects immune system activity and carries important safety risks. The US prescribing information includes boxed warnings concerning serious infections, increased mortality, malignancy, major adverse cardiovascular events and thrombosis.
Olumiant may not be appropriate for everyone. A doctor should carefully assess patients with:
Baricitinib may cause harm to an unborn baby based on animal studies. Patients who are pregnant, planning pregnancy or breastfeeding should discuss the potential risks and benefits with their healthcare professional before using Olumiant.
Olumiant may interact with other medicines that affect immune system activity or drug transport. Inform your doctor about all prescription medicines, over-the-counter products and supplements you currently use.
Particular attention is required when using:
Combining Olumiant with certain immunosuppressive medicines is not recommended for some approved indications.
Olumiant is a prescription medicine containing baricitinib, a Janus kinase (JAK) inhibitor used to treat certain autoimmune and inflammatory conditions.
Olumiant is primarily used for eligible patients with moderately to severely active rheumatoid arthritis and severe alopecia areata. It also has a US-approved indication for certain hospitalized adults with COVID-19.
Yes. Olumiant can help promote hair regrowth in some patients with severe alopecia areata, an autoimmune condition that causes hair loss. Individual results may vary, and treatment requires medical supervision.
Hair regrowth may take several months. Clinical response varies between patients, and continued treatment may be necessary to maintain improvement. Your dermatologist can assess your progress and determine the appropriate treatment duration.
No. Olumiant is not a corticosteroid. It is a targeted Janus kinase inhibitor that modifies specific immune signalling pathways.
Olumiant is prescribed as a once-daily oral medication for certain approved indications. The treatment schedule and duration must be determined by a qualified healthcare professional.
Yes. Olumiant can generally be taken with or without food according to its prescribing information.
Olumiant tablets are available in 1 mg, 2 mg and 4 mg strengths in the US prescribing information. Actual availability may differ by country and market.
Olumiant modifies immune system activity by inhibiting JAK1 and JAK2 signalling. This can increase susceptibility to certain infections, including serious infections such as tuberculosis.
Important risks include serious infections, blood clots, cardiovascular events, malignancies and changes in blood cell counts. Medical evaluation and regular monitoring are important during treatment.
Weight gain is not among the most commonly reported adverse reactions listed in the prescribing information. Contact your doctor if you notice unexplained weight changes during treatment.
Yes. Olumiant is approved in the United States for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blocker treatments.
No. Olumiant is a prescription medication and should only be used following assessment and prescription by an appropriately qualified healthcare professional.
Follow your doctor's or pharmacist's instructions. Do not take a double dose to make up for a missed tablet.
Store Olumiant according to the storage instructions printed on its original packaging. Keep it away from children and protect it from unsuitable storage conditions.
Olumiant is a potent prescription medicine that requires appropriate patient selection, baseline medical assessment and follow-up monitoring. Before starting treatment, healthcare professionals may evaluate tuberculosis status, blood counts, kidney function, liver function and other relevant health parameters.
Patients should report new infections, unexplained fever, persistent cough, chest discomfort, unusual bruising or symptoms suggestive of blood clots promptly.
Olumiant (Baricitinib) is an oral JAK inhibitor used in the treatment of selected autoimmune and inflammatory conditions. Its targeted mechanism of action makes it an important treatment option for eligible patients with rheumatoid arthritis and severe alopecia areata. However, it carries significant safety warnings and requires prescription-based use and appropriate medical monitoring.
This product description is intended for general educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. Product indications, strengths, dosage recommendations and regulatory approvals may vary by country. Always consult a qualified healthcare professional and refer to the locally approved prescribing information before using Olumiant.
USD $59.95
Products matching the full generic name: Baricitinib
Olumiant (Baricitinib) is a prescription Janus kinase (JAK1/JAK2) inhibitor used to treat certain autoimmune and inflammatory conditions, including moderately to severely active rheumatoid arthritis and severe alopecia areata. It works by regulating immune system signalling to reduce inflammation and autoimmune activity. Available in oral tablet strengths of 1 mg, 2 mg and 4 mg, depending on market availability. Use only under medical supervision due to potential serious side effects, including infections, blood clots and cardiovascular risks.
Health Guides